TY - JOUR
T1 - Muscle weakness after repeated injection of botulinum toxin type A evaluated according to bite force measurement of human masseter muscle
AU - Kim, Ki Seo
AU - Byun, Young Sub
AU - Kim, Yong Jeong
AU - Kim, Seong Taek
PY - 2009/12
Y1 - 2009/12
N2 - BACKGROUND Botulinum toxin type A (BTX-A) has been applied successfully to treat masseteric hypertrophy, but it can cause muscle weakness. OBJECTIVE To measure the change in maximum bite force (MBF) after BTX-A injection into the human masseter muscle and to evaluate the influence of a booster (repeated) injection. METHODS Thirty volunteers completed 18-week follow-up, and MBF was measured. At 18 weeks after the first injection, a booster injection was given to 14 patients, and they were followed up until 18 weeks from the booster injection. RESULTS Mean MBF was approximately 20% lower at 2 weeks than before the injection, and it recovered gradually after 4 weeks to return to the preinjection level at 12 weeks. MBF differed significantly between before the injection and at 2, 4, and 8 weeks after the injection (p<.05). In the booster injection group (n=14), MBF was markedly lower at 6 weeks (p<.05), and it recovered gradually in 12 weeks. CONCLUSION MBF was significantly lower after booster injection of BTX-A into the human masseter muscle, but it gradually recovered in a predictable pattern, and the degree of discomfort experienced by the subjects had little effect on normal mastication. This study was supported by grants from Han All Pharmaceutical Co., Seoul, Korea.
AB - BACKGROUND Botulinum toxin type A (BTX-A) has been applied successfully to treat masseteric hypertrophy, but it can cause muscle weakness. OBJECTIVE To measure the change in maximum bite force (MBF) after BTX-A injection into the human masseter muscle and to evaluate the influence of a booster (repeated) injection. METHODS Thirty volunteers completed 18-week follow-up, and MBF was measured. At 18 weeks after the first injection, a booster injection was given to 14 patients, and they were followed up until 18 weeks from the booster injection. RESULTS Mean MBF was approximately 20% lower at 2 weeks than before the injection, and it recovered gradually after 4 weeks to return to the preinjection level at 12 weeks. MBF differed significantly between before the injection and at 2, 4, and 8 weeks after the injection (p<.05). In the booster injection group (n=14), MBF was markedly lower at 6 weeks (p<.05), and it recovered gradually in 12 weeks. CONCLUSION MBF was significantly lower after booster injection of BTX-A into the human masseter muscle, but it gradually recovered in a predictable pattern, and the degree of discomfort experienced by the subjects had little effect on normal mastication. This study was supported by grants from Han All Pharmaceutical Co., Seoul, Korea.
UR - http://www.scopus.com/inward/record.url?scp=72349089530&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=72349089530&partnerID=8YFLogxK
U2 - 10.1111/j.1524-4725.2009.01319.x
DO - 10.1111/j.1524-4725.2009.01319.x
M3 - Article
C2 - 19737290
AN - SCOPUS:72349089530
SN - 1076-0512
VL - 35
SP - 1902
EP - 1907
JO - Dermatologic Surgery
JF - Dermatologic Surgery
IS - 12
ER -